AL Amyloidosis Pipeline, Emerging therapies and Drugs by DelveInsight

February 03 09:05 2021
AL Amyloidosis Pipeline, Emerging therapies and Drugs by DelveInsight

DelveInsight has launched a new report onAL Amyloidosis Pipeline

 

Amyloidosis is a rare disease resulting from abnormal protein deposits, called amyloid, in the body’s various tissues. Depending on the particular amyloid structure, the protein can accumulate in an isolated tissue or be widespread, affecting numerous organs and tissues. There are over 30 different amyloid proteins. Each amyloid protein is arranged in a structure called a fibril—low molecular weight proteins derived from precursor proteins. Fibrils of amyloid can float in the plasma of blood and deposit into tissues of the body.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight

 

AL Amyloidosis Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities

 

AL Amyloidosis Pipeline

The current therapeutic approach to systemic amyloidosis is based on the observations that organ dysfunction improves, and survival increases if the synthesis of the amyloidogenic protein precursor is halted. Therefore, the aim of therapy in AL amyloidosis is to reduce the supply of amyloidogenic  monoclonal light chains rapidly by suppressing the underlying plasma cell dyscrasia. Decisions about specific treatment regimens for individual patients must consider the balance between anticipated treatment efficacy and tolerability.

 

Emerging therapies included in the report

  • Daratumumab: Janssen Pharmaceutical
  • CAEL-101: Caelum Biosciences
  • Melflufen: Oncopeptides AB
  • Elotuzumab: Bristol-Myers Squibb
  • Evomela: Acrotech biopharma
  • Isatuximab: Sanofi

 

AL Amyloidosis Emerging Therapy

The available therapeutics treatment options in AL amyloidosis landscape aim to slow the disease progression and not stop the disease to improve survival benefits. In order to overcome the drawbacks of the treatment, a few companies are working robustly to identify the cause of disease and targeted therapy. Four major drugs are expected to enter the market by 2030.

 

AL Amyloidosis Emerging Therapy Assessment

Cardiac involvement commonly manifests as heart failure. Renal involvement usually presents as nephrotic syndrome with progressive worsening of renal functions. Thus, a significant cost burden is associated with the consequences of AL amyloidosis. There is a high rate of heart failure in patients with cardiac involvement, and the cost of a heart-failure related hospitalization is expensive but overshadowed by the high cost of heart transplant (the mean costs to Medicare per heart failure patient ranged from USD 28,766 to USD 36,216).

Patients with renal involvement may require dialysis and, eventually, kidney transplant, depending on the effectiveness of disease treatment and/or the need for pre-treatment transplants.

 

AL Amyloidosis Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence AL Amyloidosis R&D. The therapies under development are focused on novel approaches to treat/improve AL Amyloidosis.
  • CAEL-101 has received Orphan Drug Designation from both the US Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis.
  • In January 2019 Alexion Pharmaceuticals and Caelum Biosciences announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis.
  • In May 2020, Sorrento Therapeutics announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight

Table of content

  • Introduction
  • Executive Summary
  • AL Amyloidosis: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • AL Amyloidosis – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • AL Amyloidosis Collaboration Deals
  • Late Stage Products (Phase III)
  • CAEL-101: Caelum Biosciences
  • Mid Stage Products (Phase II)
  • Bendamustine – Astellas Pharma GmbH
  • Early Stage Products (Phase I)
  • STI-6129: Sorrento Therapeutics
  • Pre-clinical and Discovery Stage Products
  • Drug Name: Company Name
  • Inactive Products
  • AL Amyloidosis Key Companies
  • AL Amyloidosis Key Products
  • AL Amyloidosis- Unmet Needs
  • AL Amyloidosis- Market Drivers and Barriers
  • AL Amyloidosis- Future Perspectives and Conclusion
  • AL Amyloidosis Analyst Views
  • AL Amyloidosis Key Companies
  • Appendix

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/dispurnewsflash.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7